Fortress Biotech
FBIOFortress Biotech, Inc. is a biopharmaceutical company that specializes in the acquisition, development, and commercialization of clinical-stage assets and marketed products.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Fortress Biotech, Inc. is a biopharmaceutical company that specializes in the acquisition, development, and commercialization of clinical-stage assets and marketed products. The company operates through a hub-and-spoke model, leveraging a network of academic and industry partners to identify promising therapies and then managing them through a portfolio of subsidiary and partner companies to generate value via product sales, equity holdings, and royalty streams.
Fortress utilizes a unique diversified model that mitigates clinical risk by managing a broad portfolio of independent subsidiaries and partner companies focused on late-stage or niche assets.
Questions, answered.
- What is Fortress Biotech's market cap?
- Fortress Biotech (FBIO) has a market capitalization of $109.3M and trades on NASDAQ.
- Who are Fortress Biotech's competitors?
- Fortress Biotech's key competitors include BridgeBio Pharma, Inc., Roivant Sciences Ltd., Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Fortress Biotech partner with?
- Fortress Biotech's notable partners include City of Hope National Medical Center, Dana-Farber Cancer Institute, Nationwide Children’s Hospital, and others.
- What subsidiaries does Fortress Biotech have?
- Fortress Biotech's subsidiaries include Journey Medical Corporation, Mustang Bio, Inc., Avenue Therapeutics, Inc., and others.
- Where is Fortress Biotech headquartered?
- Fortress Biotech is headquartered in United States of America and employs approximately 186 people. It has been publicly traded since 2011.